Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarket Surveillance, 6036-6037 [2010-2458]
Download as PDF
<![CDATA[
6036
Federal Register / Vol. 75, No. 24 / Friday, February 5, 2010 / Notices
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–5156,
Daniel.Gittleson@fda.hhs.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0033]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Postmarket
Surveillance
AGENCY:
HHS.
ACTION:
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information before
submitting the collection to OMB for
approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
SUPPLEMENTARY INFORMATION:
Food and Drug Administration,
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
information collection requirements for
Postmarket Surveillance.
DATES: Submit written or electronic
comments on the collection of
information by April 6, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Postmarket Surveillance—21 CFR Part
822 (OMB Control Number 0910–
0449)—Extension
Section 522(a) of the Federal Food,
Drug and Cosmetic Act (the act) (21
U.S.C. 360l) authorizes FDA to require
manufacturers to conduct postmarket
surveillance (PS) of any device that
meets the criteria set forth in the statute.
The PS regulation establishes
procedures that FDA uses to approve
and disapprove PS plans. The regulation
provides instructions to manufacturers
so they know what information is
required in a PS plan submission. FDA
reviews PS plan submissions in
accordance with part 822 (21 CFR part
822) in §§ 822.15 to 822.19 of the
regulation, which describe the grounds
for approving or disapproving a PS plan.
In addition, the PS regulation provides
instructions to manufacturers to submit
interim and final reports in accordance
with § 822.38.
Respondents to this collection of
information are those manufacturers
who require postmarket surveillance of
their products.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
No. of
Respondents
822.9,
822.10
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
21
1
21
120
2,520
822.21 (supplements)
5
1
5
40
200
822.28 (stop marketing)
5
1
5
8
40
822.29 (request waiver)
1
1
1
40
40
822.30 (request exemption)
1
1
1
40
40
40
1
40
40
1,600
srobinson on DSKHWCL6B1PROD with NOTICES
822.38 (reports)
Total
1 There
4,440
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Nov<24>2008
16:26 Feb 04, 2010
Jkt 220001
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
E:\FR\FM\05FEN1.SGM
05FEN1
6037
Federal Register / Vol. 75, No. 24 / Friday, February 5, 2010 / Notices
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
Annual Frequency
per Recordkeeping
Total Annual
Record
Hours per
Records
Total Hours
822.31
21
1
21
20
420
822.32
63
1
63
10
630
Total
1 There
1,050
are no capital costs or operating and maintenance costs associated with this collection of information.
Explanation of Reporting Burden
Estimate
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The burden captured in table 1 for
this document for each of these
responses is based on the data available
in FDA’s internal tracking system for
2009. There was not an internal tracking
system prior to 2009.
Sections 822.26, 822.27, and 822.34
do not constitute information collection
subject to review under the PRA
because ‘‘it entails no burden other than
that necessary to identify the
respondent, the date, the respondent’s
address, and the nature of the
instrument.’’ (5 CFR 1320.3(h)(1)).
Food and Drug Administration
Explanation of Recordkeeping Burden
Estimate
srobinson on DSKHWCL6B1PROD with NOTICES
FDA expects that at least some of the
manufacturers will be able to satisfy the
PS requirement using information or
data they already have. For purposes of
calculating burden, however, FDA has
assumed that each PS order can only be
satisfied by a 3-year clinically-based
surveillance plan, using three
investigators. These estimates are based
on FDA’s knowledge and experience
with limited implementation of section
522 under the Safe Medical Devices Act.
Therefore, FDA would expect that the
recordkeeping requirements would
apply to a maximum of 21
manufacturers (3 to 4 added each year)
and 30 investigators (3 per surveillance
plan). After 3 years, FDA would expect
these numbers to remain level as the
surveillance plans conducted under the
earliest orders reach completion and
new orders are issued.
Dated: January 27, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
[FR Doc. 2010–2458 Filed 2–4–10; 8:45 am]
BILLING CODE 4160–01–S
VerDate Nov<24>2008
16:26 Feb 04, 2010
Jkt 220001
[Docket No. FDA–2010–D–0034]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Guidance for
Industry on How to Submit a Notice of
Final Disposition of Investigational
Animals Not Intended for Immediate
Slaughter in Electronic Format to the
Center for Veterinary Medicine
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the reporting requirements for the
information collection activity ‘‘How to
Submit a Notice of Final Disposition of
Investigational Animals Not Intended
for Immediate Slaughter In Electronic
Format to the Center for Veterinary
Medicine.’’
DATES: Submit written or electronic
comments on the collection of
information by April 6, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\05FEN1.SGM
05FEN1
]]>Agencies
[Federal Register Volume 75, Number 24 (Friday, February 5, 2010)]
[Notices]
[Pages 6036-6037]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-2458]
[[Page 6036]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0033]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Postmarket Surveillance
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on information collection
requirements for Postmarket Surveillance.
DATES: Submit written or electronic comments on the collection of
information by April 6, 2010.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Postmarket Surveillance--21 CFR Part 822 (OMB Control Number 0910-
0449)--Extension
Section 522(a) of the Federal Food, Drug and Cosmetic Act (the act)
(21 U.S.C. 360l) authorizes FDA to require manufacturers to conduct
postmarket surveillance (PS) of any device that meets the criteria set
forth in the statute.
The PS regulation establishes procedures that FDA uses to approve
and disapprove PS plans. The regulation provides instructions to
manufacturers so they know what information is required in a PS plan
submission. FDA reviews PS plan submissions in accordance with part 822
(21 CFR part 822) in Sec. Sec. 822.15 to 822.19 of the regulation,
which describe the grounds for approving or disapproving a PS plan. In
addition, the PS regulation provides instructions to manufacturers to
submit interim and final reports in accordance with Sec. 822.38.
Respondents to this collection of information are those
manufacturers who require postmarket surveillance of their products.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.9, 21 1 21 120 2,520
822.10
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.21 (supplements) 5 1 5 40 200
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.28 (stop marketing) 5 1 5 8 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.29 (request waiver) 1 1 1 40 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.30 (request exemption) 1 1 1 40 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.38 (reports) 40 1 40 40 1,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 4,440
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 6037]]
Table 2.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Recordkeepers per Recordkeeping Record Records Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.31 21 1 21 20 420
--------------------------------------------------------------------------------------------------------------------------------------------------------
822.32 63 1 63 10 630
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 1,050
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Explanation of Reporting Burden Estimate
The burden captured in table 1 for this document for each of these
responses is based on the data available in FDA's internal tracking
system for 2009. There was not an internal tracking system prior to
2009.
Sections 822.26, 822.27, and 822.34 do not constitute information
collection subject to review under the PRA because ``it entails no
burden other than that necessary to identify the respondent, the date,
the respondent's address, and the nature of the instrument.'' (5 CFR
1320.3(h)(1)).
Explanation of Recordkeeping Burden Estimate
FDA expects that at least some of the manufacturers will be able to
satisfy the PS requirement using information or data they already have.
For purposes of calculating burden, however, FDA has assumed that each
PS order can only be satisfied by a 3-year clinically-based
surveillance plan, using three investigators. These estimates are based
on FDA's knowledge and experience with limited implementation of
section 522 under the Safe Medical Devices Act. Therefore, FDA would
expect that the recordkeeping requirements would apply to a maximum of
21 manufacturers (3 to 4 added each year) and 30 investigators (3 per
surveillance plan). After 3 years, FDA would expect these numbers to
remain level as the surveillance plans conducted under the earliest
orders reach completion and new orders are issued.
Dated: January 27, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2010-2458 Filed 2-4-10; 8:45 am]
BILLING CODE 4160-01-S
